Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Infliximab

Study type: Observational

Funder types: Industry

Identifiers

NCT00724243

P04741

Details and patient eligibility

About

This study will gather information on the safety and efficacy of patients with rheumatoid arthritis (RA) who are starting treatment with infliximab for the first time. Patients will be treated in the usual manner according to local guidelines and normal clinical practice.

Full description

Local patients, diagnosed with RA at the National Institute of Rheumatic Diseases, Piestany, Slovakia, can participate, if their physicians have decided to treat the patient with infliximab. Registration for the trial will be done on a voluntary basis.

Enrollment: 33 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must have been given patient leaflet,
• Subject must not have ever received infliximab at the time of registration,
• Subject must be a good candidate for infliximab as per Summary of Product Characteristics
• Subject must sign the approved consent form

Exclusion criteria

• None

Trial design

33 participants in 1 patient group

Rheumatoid Arthritis Patients in Slovakia

Description:

Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.

Treatment:

Drug: Infliximab